These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36203787)

  • 1. Multiple Dose Pharmacokinetics of Tapentadol Oral Solution for the Treatment of Moderate to Severe Acute Pain in Children Aged 2 to <7 Years.
    Jończyk R; Beuter C; Bulawa B; Buller S; Eibl C; Elling C; Gautrois M; Rengelshausen J; Schmidt C; Thömmes G; Khalil F
    J Pain Res; 2022; 15():3103-3114. PubMed ID: 36203787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tapentadol for the Treatment of Moderate-to-Severe Acute Pain in Children Under the Age of Two Years.
    Eissa A; Tarau E; Beuter C; Radic T; Watson E; Sohns M; Lefeber C; Hammer GB
    J Pain Res; 2021; 14():229-248. PubMed ID: 33542653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetic modeling to facilitate dose selection of tapentadol in the pediatric population.
    Watson E; Khandelwal A; Freijer J; van den Anker J; Lefeber C; Eerdekens M
    J Pain Res; 2019; 12():2835-2850. PubMed ID: 31686902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First evaluation of tapentadol oral solution for the treatment of moderate to severe acute pain in children aged 6 to <18.
    Finkel JC; Goldberg J; Rosenburg R; Ariyawansa J; Sun T; Ochs-Ross R; Zannikos P; Zhang L; Etropolski M
    J Pain Res; 2019; 12():1925-1936. PubMed ID: 31303784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, safety, and efficacy of tapentadol oral solution for treating moderate to severe pain in pediatric patients.
    Muse D; Tarau E; Lefeber C; Sohns M; Brett M; Goldberg J; Rosenburg R
    J Pain Res; 2019; 12():1777-1790. PubMed ID: 31213888
    [No Abstract]   [Full Text] [Related]  

  • 6. Population pharmacokinetics of tapentadol immediate release (IR) in healthy subjects and patients with moderate or severe pain.
    Xu XS; Smit JW; Lin R; Stuyckens K; Terlinden R; Nandy P
    Clin Pharmacokinet; 2010 Oct; 49(10):671-82. PubMed ID: 20818833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of multiple doses of tapentadol oral solution in the treatment of moderate to severe acute pain in children aged 2 to <18 years - a randomized, double-blind, placebo-controlled trial.
    Beuter C; Volkers G; Radic T; Goldberg J; van den Anker J
    J Pain Res; 2019; 12():3099-3112. PubMed ID: 32009813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetics of Tapentadol in Children from Birth to <18 Years Old.
    Khalil F; Choi SL; Watson E; Tzschentke TM; Lefeber C; Eerdekens M; Freijer J
    J Pain Res; 2020; 13():3107-3123. PubMed ID: 33262645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tapentadol immediate release versus oxycodone immediate release for treatment of acute low back pain.
    Biondi D; Xiang J; Benson C; Etropolski M; Moskovitz B; Rauschkolb C
    Pain Physician; 2013; 16(3):E237-46. PubMed ID: 23703422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations.
    Göhler K; Brett M; Smit JW; Rengelshausen J; Terlinden R
    Int J Clin Pharmacol Ther; 2013 Apr; 51(4):338-48. PubMed ID: 23357834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics after oral administration of tapentadol hydrochloride in dogs.
    Howard J; Aarnes TK; Dyce J; Lerche P; Wulf LW; Coetzee JF; Lakritz J
    Am J Vet Res; 2018 Apr; 79(4):367-375. PubMed ID: 29583048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose conversion between tapentadol immediate and extended release for low back pain.
    Etropolski MS; Okamoto A; Shapiro DY; Rauschkolb C
    Pain Physician; 2010; 13(1):61-70. PubMed ID: 20119464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic evaluation of tapentadol extended-release tablets in healthy subjects.
    Zannikos PN; Smit JW; Stahlberg HJ; Wenge B; Hillewaert VM; Etropolski MS
    J Opioid Manag; 2013; 9(4):291-300. PubMed ID: 24353023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tapentadol hydrochloride: a centrally acting oral analgesic.
    Wade WE; Spruill WJ
    Clin Ther; 2009 Dec; 31(12):2804-18. PubMed ID: 20110020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release.
    Imanaka K; Tominaga Y; Etropolski M; Ohashi H; Hirose K; Matsumura T
    Clin Drug Investig; 2014 Jul; 34(7):501-11. PubMed ID: 24906437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
    Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
    CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of oral tapentadol in cats.
    Lakritz J; Aarnes TK; Alva B; Howard J; Magnin G; Lerche P; Kukanich B
    J Vet Pharmacol Ther; 2024 Jan; 47(1):14-20. PubMed ID: 37350452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tapentadol immediate release for moderate to severe acute post-surgery pain.
    Viscusi ER; Allard R; Sohns M; Eerdekens M
    J Opioid Manag; 2019; 15(1):51-67. PubMed ID: 30855723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers.
    Darwish M; Yang R; Tracewell W; Robertson P; Bond M
    Clin Ther; 2015 Feb; 37(2):390-401. PubMed ID: 25542074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Effectiveness and Tolerability of Pain Treatment with Tapentadol Prolonged Release.
    Mateos RG; Bernal DS; Morera LMT; Ferri CM; Escobar AE
    Pain Physician; 2021 Jan; 24(1):E75-E85. PubMed ID: 33400440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.